The consensus of ER signatures from the 206 combined breast cancer samples resulted in a list of 36 genes, including NME3, ADCY9, WDR90, IKBKB, SRP14, WWP1, GPR160, ERI2, CDIPT, TCEA3, FLJ10661, S100PBP, GLIS2, FLYWCH2, METRN, TRNAU1AP, RSC1A1, TRIM45, HAGH, FDXR, C16orf52, ZNF720, STK40, SLCO4A1, ELOVL1, ADRM1, PDZK1IP1, CHCHD10, SMCR7L, WDR77, RTN4R, THOC5, HPDL, HENMT1, UQCRH, and MRPL37. The predictive accuracy was 89-93% across the various validation methods (Table 3). The gene discussed is GPR160; the disease is breast carcinoma.